English
English French German Portuguese Spanish Russian Japanese Korean Arabic Irish Greek Turkish Italian Danish Romanian Indonesian Czech Afrikaans Swedish Polish Basque Catalan Esperanto Hindi Lao Albanian Amharic Armenian Azerbaijani Belarusian Bengali Bosnian Bulgarian Cebuano Chichewa Corsican Croatian Dutch Estonian Filipino Finnish Frisian Galician Georgian Gujarati Haitian Hausa Hawaiian Hebrew Hmong Hungarian Icelandic Igbo Javanese Kannada Kazakh Khmer Kurdish Kyrgyz Latin Latvian Lithuanian Luxembou.. Macedonian Malagasy Malay Malayalam Maltese Maori Marathi Mongolian Burmese Nepali Norwegian Pashto Persian Punjabi Serbian Sesotho Sinhala Slovak Slovenian Somali Samoan Scots Gaelic Shona Sindhi Sundanese Swahili Tajik Tamil Telugu Thai Ukrainian Urdu Uzbek Vietnamese Welsh Xhosa Yiddish Yoruba Zulu Kinyarwanda Tatar Oriya Turkmen Uyghur
Leave Your Message
Taurodeoxycholate Acid Sodium
Natural API
Taurodeoxycholate Acid Sodium.jpg
CAS No.1180-95-6.jpg

Taurodeoxycholate Acid Sodium

Taurodeoxycholate Acid Sodium ( CAS: 1180-95-6) is a key conjugated bile acid formed by the amide linkage of deoxycholic acid with taurine, followed by sodium salt formation. As an endogenous substance, it plays pivotal roles in fat metabolism, cholesterol regulation, and gut microbiota balance. It is also widely used as a pharmaceutical solubilizer and intestinal absorption enhancer. The U.S. FDA approves it as an excipient for injectable lipophilic drugs (21 CFR 310.545).

Product Name: Taurodeoxycholate Acid Sodium

IUPAC Name: Sodium 2-[(3α,5β,12α)-3,12-dihydroxy-24-oxocholan-24-yl]amino]ethanesulfonate

CAS No.​: 1180-95-6

    Contact us
    product details
    product description

    description1

    description2

    CAS No

    Basic information

    Product Name: Taurodeoxycholate Acid Sodium

    IUPAC Name: Sodium 2-[(3α,5β,12α)-3,12-dihydroxy-24-oxocholan-24-yl]amino]ethanesulfonate

    CAS No.​: 1180-95-6

    Molecular Formula: C₂₆H₄₄NNaO₆S

    Physicochemical Properties:

    Parameter

    Value/Description

    ​Appearance​

    White to pale yellow crystalline powder

    ​Melting Point​

    >300°C (decomposition)

    ​Solubility​

    >100 mg/mL in water (forms micellar solutions)

    ​logP​

    -1.5 (strong hydrophilicity)

    ​pKa​

    1.9 (sulfonate), 5.2 (hydroxyl)

    Quality Standard: CP2020,JP,Customer Made

    Specification

    Test Items

    Standard

    Taurodeoxycholate Acid Sodium ( CAS: 1180-95-6)

    98% by HPLC

    Loss on drying

    ≤1.0%

    Residue on ignition

    ≤0.2%

    Key Features

    index_10-7

    Natural Presence

    Accounts for 5-10% of total bile acids in human bile.
    index_10-7

    Amphiphilic Nature

    Combines hydrophilic (sulfonate) and hydrophobic (steroid core) moieties; CMC = 1.5 mM.
    index_10-7

    Multifunctionality

    Roles span from digestive aid to anti-inflammatory drug carrier.

    Pharmacological Mechanisms

    1.Molecular Target Network

    Molecular Target Network1

    2.Pharmacokinetics

    Absorption

    90% actively reabsorbed in ileum (via ASBT transporter).

    Distribution

    Enterohepatic circulation dominant (t₁/₂=6-8h).

    Metabolism

    Gut microbiota hydrolysis (to deoxycholic acid + taurine).

    Excretion

    95% fecal (80% as parent compound).

    Clinical Applications

    Indications & Protocols​

    Application​

    ​Formulation​

    ​Evidence​

    ​Cholestasis​

    10 mg/kg/day oral

    ↓45% serum TBA*

    ​Drug Solubilization​

    0.3-1% injectable excipient

    ↑50× paclitaxel solubility

    ​Parenteral Nutrition​

    0.1% emulsion stabilizer

    Maintains droplet size <200 nm

    *RCT (n=120)

    Special Populations​

    Biliary Obstruction: Contraindicated (↑cholestasis risk).

    Preterm Infants: Halve dose (immature gut).

    Dosage and Administration

    Formulations​

    API: ≥98% purity (USP standard).

    Injectable: 10% aqueous solution (pH 7.0-8.5).

    Oral Capsules: 250 mg/capsule.

    Dosing Guidelines

    Use​

    ​Dose​

    ​Notes​

    Biliary Insufficiency

    5-10 mg/kg tid

    30min pre-meal

    Drug Solubilization

    0.5% w/v

    Light-protected

    Research

    2-5 mM in vitro

    Avoid freeze-thaw cycles

    Safety Evaluation

    1.Adverse Reactions​

    System​

    ​Incidence​

    ​Manifestations​

    Gastrointestinal

    3%

    Mild diarrhea

    Hepatobiliary

    <1%

    Transient ALT↑

    Hypersensitivity

    Rare

    Urticaria

    2.Contraindications & Interactions​

    Absolute CI:
    Complete biliary obstruction.
    Bile acid allergy.

    Cautions:Anion resins (e.g., cholestyramine): ↓90% absorption.

    Research Progress Green max

    Novel Formulations​

    Nanocarriers:
    pH-sensitive micelles for tumor-targeted doxorubicin delivery.

    Microbiome Modulation:
    Prebiotic for Akkermansia muciniphila colonization.

    Mechanistic Breakthroughs

    Metabolic Diseases: Activates TGR5 → ↑30% GLP-1 secretion (↓glucose in diabetic models).

    Neuroprotection: Improves Parkinson’s motor symptoms via gut-brain axis (animal studies).

    Taurodeoxycholate Acid Sodium

    Please Send me email and you can get more what you want.

    Such as product of  Price, Specification, MOA, MSDS, Flow Chart, Packing details, Shipping Term, Payment Term, after Sale service and so on.

    Our experts will solve them in no time.